This article was originally published by Sajna T. in Management Insight, 16(1):38-40 under a creative commons license. Abstract Business enterprises are an important organ of society. The impact of a…
Posts published in “Guest Content”
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain patent-term extensions for drugs, pesticides or agricultural chemicals, a careful…
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted at isacsonj@pepperlaw.com and Nicole can be contacted at stakleffn@pepperlaw.com. The Federal Circuit recently…
Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin Hatch to pass the Hatch-Waxman Act and its aftermath. Congressman…
This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
0
This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2018; 361 under…
This paper was originally published by Glenn P. Carroll, Sanjay Srivastava, Adam S. Volini, Marta M. Piñeiro-Núñez, and TatianaVetman in Drug Discovery Today Volume 22, Issue 5, May 2017, Pages 776-785 under…
This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persistent gaps in access…
Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets
0
This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
